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PCardiac Imaging
Imaging of Vascular Inflammation With
[11C]-PK11195 and Positron Emission Tomography/
Computed Tomography Angiography
Francesca Pugliese, MD, PHD,* Oliver Gaemperli, MD,* Anne R. Kinderlerer, MD,†
Frederic Lamare, PHD,* Joseph Shalhoub, BSC,‡ Alun Huw Davies, MA, DM,‡
Ornella E. Rimoldi, MD,* Justin C. Mason, PHD,† Paolo G. Camici, MD*§
London, United Kingdom; and Milan, Italy
Objectives We sought to investigate whether positron emission tomography/computed tomography (CT) angiography using
[11C]-PK11195, a selective ligand for peripheral benzodiazepine receptors expressed in activated macrophages,
can be used to image vascular inflammation.
Background Activated macrophages and T lymphocytes are fundamental elements in the pathogenesis of large-vessel vasculitides.
Methods Fifteen patients (age 52  16 years) with systemic inflammatory disorders (6 consecutive symptomatic patients
with clinical suspicion of active vasculitis and 9 asymptomatic control patients) underwent positron emission
tomography with [11C]-PK11195 and CT angiography. [11C]-PK11195 uptake was measured by calculating
target-to-background ratios of activity normalized to venous blood.
Results Coregistration of positron emission tomography with contrast-enhanced CT angiography facilitated localization of
[11C]-PK11195 arterial wall uptake. Visual analysis revealed focal [11C]-PK11195 uptake in the arterial wall of
all 6 symptomatic patients, but in none of the asymptomatic controls. Although serum inflammatory biomarkers
(C-reactive protein, erythrocyte sedimentation rate, white cell count) did not differ significantly between the
2 groups, symptomatic patients had increased [11C]-PK11195 vascular uptake (target-to-background ratio
2.41  1.59 vs. 0.98  0.10; p  0.001).
Conclusions By binding to activated macrophages in the vessel wall, [11C]-PK11195 enables noninvasive imaging of vascular
inflammation. Alternative longer-lived radioligands for probing peripheral benzodiazepine receptors are being
tested for wider clinical applications. (J Am Coll Cardiol 2010;56:653–61) © 2010 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.02.063a
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carge-vessel vasculitides such as giant cell arteritis (GCA)
nd Takayasu’s arteritis (TA) are characterized by granulo-
atous pan-arteritis with focal leukocytic infiltration. The
nflammatory infiltrates may cause thickening of the in-
olved artery and lead to luminal narrowing and occlusion.
ilation, aneurysm formation, and thrombosis may also
nsue (1,2). These patients are also at risk from accelerated
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Manuscript received December 8, 2009; accepted February 9, 2010.therosclerosis when compared with age-matched controls,
urther increasing their cardiovascular morbidity and mor-
ality (2,3).
Activated macrophages and T lymphocytes are funda-
ental elements in the pathogenesis of GCA and TA (2).
he ligand PK11195 binds to the peripheral benzodiaz-
pine receptor (PBR), a protein that is highly expressed in
ctivated cells of the mononuclear phagocyte lineage. Since
he early 1980s, [11C]-PK11195 has been used in combi-
ation with positron emission tomography (PET) to image
nflammatory diseases in the human brain on the basis of
he low expression of PBRs in normal brain tissue and high
xpression in activated microglia, the resident phagocytes in
rain tissue, during neuroinflammation (4,5).
More recently, specific in vitro binding of [3H]-PK11195
o macrophages has been shown in human carotid endar-
erectomy samples, suggesting its potential value as a spe-
ific marker of vascular inflammation (6). In view of the
bundance of activated macrophages characteristic of GCA
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Imaging Vascular Inflammation August 17, 2010:653–61and TA, we hypothesized that
patients with large-vessel vascu-
litides would be an ideal target
for a proof of principle study
to ascertain whether PET with
[11C]-PK11195 in combination
with computed tomography (CT)
angiography can be used to im-
age vascular inflammation.
Methods
Study population. From Impe-
rial College Healthcare National
Health Service Trust rheuma-
tology clinics, 15 patients with
systemic inflammatory disorders
(GCA, TA, and systemic lupus
erythematosus [SLE]) were en-
rolled. Of these, 6 consecutive
patients with large-vessel vascu-
litis were chosen due to a high
clinical index of suspicion of ac-
tive disease. Active vasculitis was
defined as onset within the pre-
vious 3 months of any of the
ollowing symptoms: visual disturbance, headache, bruit or
ascular pain/tenderness, new claudication, fever, night
weats, and/or arthralgia.
The remaining 9 patients were consecutive asymptomatic
atients (defined as absence of symptoms of active disease) who
ttended the clinic for routine follow-up. For SLE, the
ystemic Lupus Erythematosus Disease Activity Index was
sed to assess disease activity (7). Exclusion criteria for all
atients were known intolerance to iodinated contrast agent,
nability to lie flat, age 25 or 80 years, and claustrophobia.
n all patients, blood samples were obtained within a week of
ET/CT imaging to measure C-reactive protein (CRP),
rythrocyte sedimentation rate (ESR), and white blood cell
ount. The study protocol was approved by the local research
thics committee, and all patients gave written informed
onsent. Radiation exposure was licensed by the U.K. Admin-
stration of Radioactive Substances Advisory Committee.
adiotracer synthesis. [11C]-PK11195 was prepared as
escribed by Tomasi et al. (8). In brief, [11C]-methyl iodide
as incubated with 1.0 mg of desmethyl-PK11195 (ABX,
adeberg, Germany) and 1.0 mg of powdered potassium
ydroxide in 200 l of dimethyl sulfoxide for 1.5 min at
0°C. The crude product was purified on a semi-preparative
henomenex Ultracarb 7 ODS 250  10-mm column
sing 70% ethanol, 30% water as the high-performance
iquid chromatography (HPLC) solvent. After evaporation
f the HPLC solvent, the purified product was formulated
n 0.9% saline with 5% ethanol and filtered through a
.22-m sterile filter. Measurement of concentration and
Abbreviations
and Acronyms
CRP  C-reactive protein
CT  computed
tomography
ESR  erythrocyte
sedimentation rate
FDG  [18F]-
fluorodeoxyglucose
GCA  giant cell arteritis
HPLC  high-performance
liquid chromatography
PBR  peripheral
benzodiazepine receptor
PET  positron emission
tomography
ROI  region of interest
SLE  systemic lupus
erythematosus
SUV  standardized uptake
value
TA  Takayasu’s arteritis
TBR  target-to-
background ratioadiochemical purity of [11C]-PK11195 batches was per- aormed by HPLC using an analytical Luna C8 150 
.6-mm column (Phenomenex), a UV detector set at 277
m, and a radioactivity detector in series. Radiochemical
urity was 99.5%.
ET/CT imaging. Imaging was performed using a 16-
lice PET/CT scanner (Discovery RX, GE Healthcare,
ilwaukee, Wisconsin) with a 15-cm field of view. After
cquisition of the localizer, a low-dose CT scan was
cquired in helical mode for attenuation correction with the
ollowing parameters: 120 kV, 20 mAs, 8  2.5-mm slice
hickness, pitch of 1.675, 0.5-s rotation time. A line passing
cm below the carina was used as lower limit of the PET field
f view, which thus encompassed the aortic arch, common
arotid arteries, and carotid bifurcations. After injection of 6.85
Bq/kg of [11C]-PK11195, PET emission data were acquired
ver 60 min in list mode format and rebinned into 18 temporal
rames (30-s background, 1 15 s, 1 5 s, 1 10 s, 1 30 s,
 60 s, 7  300 s, and 2  600 s).
After the PET scan, CT angiography was performed
ith the same field of view as the PET scan. A bolus of 70
l of contrast (Ultravist 370, Schering, Berlin, Germany)
as injected at a rate of 3.5 ml/s into an antecubital vein. A
olus tracking technique was used to synchronize the arrival
f contrast in the ascending aorta with the CT angiography
can. The CT angiography acquisition parameters were 120
V, 180 mAs, 16  0.625-mm slice thickness, pitch of 1.0,
.5-s rotation time. Using these parameters, scan times for
T angiography were in the range of 12 to 16 s. The
ffective dose of CT (including localizer, attenuation cor-
ection, and CT angiography) was estimated from the
roduct of the dose-length product and an organ-weighting
actor for the chest (0.014 mSv  mGy1  cm1) as
roposed by the European Working Group for Guidelines
n Quality Criteria in CT (9,10).
mage reconstruction. All emission scans were normalized
nd corrected for randoms, dead time, scatter, and attenu-
tion and were reconstructed using an ordered subset
xpectation maximization algorithm with 2 iterations and
1 subsets. Frames 10 to 14 were added to obtain the image
or visual analysis and uptake measurement.
Reconstruction parameters for CT angiography were
.625-mm slice thickness, 0.625-mm increment, 30-cm-
ide reconstruction field of view, window width of 300
ounsfield units, and window level of 30 Hounsfield units.
mage coregistration and visual analysis. Using a dedi-
ated workstation (Advantage Workstation 4.2, GE Health-
are), images were inspected visually for [11C]-PK11195
ptake by 1 operator unaware of patient history, ongoing
edications, and biomarker results. In the event of mis-
lignment between the CT and the PET datasets, images
ere realigned manually using anatomical landmarks such
s the vertebrae and the sternum, which showed marked
racer uptake. Visual analysis was performed on axial source
lices, and sagittal, coronal, and oblique reformations of the
scending, arch, and descending aorta. The aorta or carotid
rteries were considered positive for active inflammation
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August 17, 2010:653–61 Imaging Vascular Inflammationhen heterogeneously increased [11C]-PK11195 uptake
as seen in areas corresponding to the aortic or carotid wall
n CT angiography.
emiquantitative measurement of [11C]-PK11195 uptake.
T images were reduced to a matrix size of 128  128 
7 to match the size of the reconstructed PET images and
uperimposed to the PET images to help define the regions
f interest (ROIs). Images were then re-sliced with a slice
hickness of 1 mm to obtain cross-sections of the ascending,
rch, and descending aorta, and ROIs were placed encom-
assing the wall of aorta and carotid arteries using dedicated
oftware (MATLAB software, The MathWorks Inc.,
atick, Massachusetts). The average volume of interest was
.2 1.0 ml for the carotid arteries and 4.0 2.5 ml for the
orta. To quantify tracer uptake in the vessel wall, standard-
zed uptake values (SUVs) were calculated as the mean tissue
ctivity concentration in each volume of interest (in Bq/ml)
ivided by total injected activity per body weight (in Bq/g).
background SUV was obtained in a venous structure
superior vena cava, subclavian, or internal jugular vein), and
rterial wall target-to-background ratios (TBRs) were cal-
ulated as arterial wall SUV divided by venous blood SUV.
tatistical analysis. Statistical analysis was performed with
PSS version 16.0.1 (SPSS, Inc., Chicago, Illinois). Quan-
itative variables are expressed as mean  SD. Categorical
ariables are expressed as frequencies (percentages). The
ann-Whitney U test was used for comparison of quan-
itative data. A p value 0.05 was considered statistically
ignificant.
aseline CharacteristicsTable 1 Baseline Characteristics
Patient # Sex (M/F) Age (yrs) Diagnosis Presenting Symptoms
1 M 69 GCA Visual loss, headache
2 F 62 GCA Fever, arthralgia, temporal tend
3 F 43 TA Fever, headache
4 M 46 TA Fever, malaise, neck pain, carot
5 F 76 GCA Visual loss, tongue claudication
6 F 59 GCA Night sweats, scalp tenderness
7 F 25 TA —
8 F 61 TA —
9 F 73 SLE —
10 F 33 SLE —
11 F 51 TA —
12 F 51 SLE —
13 F 46 SLE —
14 F 26 SLE —
15 F 60 SLE —
rug doses are expressed per day unless otherwise stated.
CRP  C-reactive protein (normal values 5 mg/l); ESR  erythrocyte sedimentation rate (normal valu
SAID  nonsteroidal anti-inflammatory drugs; Pred  prednisolone; SLE  systemic lupus erythematosesults
atient characteristics. Mean patient age was 52  16
ears, and 13 patients were female. Five patients had TA, 4
ad GCA, and 6 had SLE. All patients fulfilled American
ollege of Rheumatology diagnostic criteria (11–13). For
LE patients, the mean Systemic Lupus Erythematosus
isease Activity Index was 6 5 (range 2 to 14). Individual
atients’ characteristics and ongoing medications are de-
cribed in Table 1.
A trend toward higher serum biomarker levels was seen in
ymptomatic patients versus asymptomatic patients (CRP,
4 46 mg/l vs. 4 6 mg/l; ESR, 42 43 mm/h vs. 33
2 mm/h; and white blood cell count, 9.7  5.5  109/l vs.
.4  2.9  109/l (p  NS). Individual levels are given in
able 1.
isual PET/CT findings. Average injected activity in our
tudy population was 446  82 MBq. [11C]-PK11195
ptake was visually detected in 6 patients, all with symptoms
uggesting active vasculitis. No evidence of significant ath-
roma was seen on CT angiography at the level of tracer
ptake in all 6 patients. In 5 patients (Patients #1 to #3, #5,
nd #6), uptake was seen at the level of the aorta. Repre-
entative images are shown for all symptomatic patients in
igures 1 and 2. In 3 of these patients (Patients #1, #5, and
6), CT angiography showed diffuse thickening of the aortic
all (up to 4 mm), coincident with maximal tracer uptake
ith minimal calcification and no evidence of atheroma
Figs. 1 and 2). In 1 patient (Patient #4) with carotidynia,
ever, and malaise, focal uptake was noted at the level of the
CRP (mg/l) ESR (mm/h) WBC (109/l) Ongoing Medications
118 124 7.9 —
5 52 6.5 Pred 2.5 mg
7 8 18 —
5 19 4.1 —
5 24 6.7 Pred 80 mg
14 25 15.2 Pred 15 mg
8 19 10.5 Pred 10 mg
Mtx 20 mg (weekly)
12 33 8.6 Pred 20 mg
5 25 7.1 Pred 4 mg
5 5 6.3 Pred 2.5 mg
HyChlor 200 mg
14 62 13 Pred 4 mg
5 38 4.0 NSAID 90 mg (when needed)
HyChlor 200 mg
Mtx 15 mg
5 20 6.7 NSAID 100 mg
HyChlor 200 mg
5 20 4.2 Pred 2.5/5 mg (alternate days)
5 75 5.8 Pred 10 mg
HyChlor 200 mg
Azathioprine 100 mgerness
odyniaes 0 to 20 mm/h); GCA  giant cell arteritis; HyChlor  hydroxychloroquine; Mtx methotrexate;
us; TA  Takayasu’s arteritis; WBC  white blood cell count (normal values 4 to 11  109/l).
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Imaging Vascular Inflammation August 17, 2010:653–61eft common carotid artery just proximal to the bifurcation.
n this patient, CT angiography showed focal thickening of
he common carotid artery wall (approximately 2 mm) at the
evel of tracer uptake in the absence of atheroma. An
ltrasound study confirmed this finding, which corre-
ponded with the region of maximal tenderness.
In 1 symptomatic patient with GCA (Patient #1) (Fig. 1),
11C]-PK11195 PET/CT images were obtained before and
fter a 20-week course of oral corticosteroids. The PET
can after treatment demonstrated that [11C]-PK11195
ptake in the wall of the aortic arch was markedly reduced,
nd TBRs decreased from 1.63 to 0.87. The reduction in
11C]-PK11195 uptake was paralleled by a distinct im-
rovement in symptoms and a decrease in his serum
nflammatory markers (ESR 124 mm/h vs. 67 mm/h and
RP 118 mg/l vs. 22 mg/l, respectively).
In the remaining 9 asymptomatic patients, no uptake was
ppreciable on visual analysis (Fig. 3). In 1 (Patient #15) of
he patients with no evidence of focal tracer uptake, minor
A
C
E
Figure 1 A 69-Year-Old Patient (Patient #1) With Visual Loss a
Hybrid [11C]-PK11195 positron emission tomography (PET)/computed tomography
oral corticosteroids. The insets in A to D show corresponding nonfused PET recon
the aortic arch (solid arrows) on coronal (A) and sagittal (B) planes. After treatme
PK11195 uptake (open arrows). Aortic wall target-to-background ratios decreased
and eosin (4 objective) showing transmural granulomatous infiltration with macro
der (*). (F) Elastica van Gieson staining showing patchy disruption of the elastic lilateral calcification was noted at the level of the carotid tifurcations. This patient had type 2 diabetes mellitus and
as on treatment with oral antidiabetic drugs. The aorta
as regular in diameter, and there were no ulcerated plaques.
Estimated mean effective radiation doses were 6.0  0.5
Sv for CT and 2.1  0.2 mSv for [11C]-PK11195 PET,
nd the mean total effective dose was 8.1  0.6 mSv.
ndividual patient doses are given in Table 2.
emiquantitative measurement of [11C]-PK11195 uptake.
ndividual TBRs for ROIs are shown in Table 2. TBR was
ignificantly higher in symptomatic compared with asymp-
omatic patients (2.41  1.59 vs. 0.98  0.10; p  0.001)
Fig. 4). None of the asymptomatic patients had a TBR
1.20, whereas none of the symptomatic patients had a
BR 1.20.
iscussion
n the present study, we demonstrate the value of PET with
11C]-PK11195 for detecting vascular inflammation in pa-
eadache at Presentation
s were obtained before (A and B) and after (C and D) a 20-week treatment with
ons. Marked [11C]-PK11195 uptake can be seen in the superior-lateral wall of
mparable image planes (C and D) demonstrate a marked reduction in [11C]-
.63 to 0.87. (E) Temporal artery biopsy specimens stained with hematoxylin
s and multinucleated giant cells in the adventitia (arrow) and media-intima bor-
(arrowheads).B
D
F
nd H
image
structi
nt, co
from 1
phage
aminaients with GCA and TA. An increased tracer uptake was
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August 17, 2010:653–61 Imaging Vascular Inflammationoted in the arterial wall of patients with active vasculitis
defined by the presence of typical systemic symptoms)
ompared with asymptomatic controls. Hence, PET with
11C]-PK11195 may be used to distinguish active inflam-
ation in patients with large-vessel vasculitis, characterized
y a macrophage-rich infiltrate, from nonactive or more
uiescent disease, where inflammatory changes are mild or
bsent (2).
In this proof of principle study, we used patients with
arge-vessel vasculitis as a model for vascular wall inflam-
ation. In this context, the amount and density of the
nflammatory infiltrate is directly linked to local disease
ctivity. Patients with large-vessel vasculitis may present
ith marked vascular infiltration and high local and sys-
Pt. #3Pt. #2
*
Pt. #5
*
Figure 2 Representative [
11C]-PK11195 PET/CT Reconstructio
in Patients With Signs and Symptoms of Active Vascu
For each patient, [11C]-PK11195 positron emission tomography (PET)/computed to
images are shown in the bottom panel. Five patients demonstrated focal [11C]-PK
focal [11C]-PK11195 in the left carotid wall (Patient #4) (white arrows). High [11C]
arrowheads). The orientation of the reconstruction was chosen for optimal visualiz
Patient #3 due to anteroposterior patient movement during image acquisition.emic inflammatory activity, leading to disruption of struc- vural components of the vessel wall and ultimately stenosis,
ilation, or occlusion of the involved arteries (1). Addition-
lly, they have an increased cardiovascular risk compared
ith healthy individuals of comparable age as a consequence
f accelerated atherosclerosis (2). Therefore, patients with
arge-vessel vasculitis constitute a suitable population for
esting the value of [11C]-PK11195 to assess vascular
nflammation in vivo.
Inflammation plays a key role in acute destabilization of
therosclerotic plaques, and dense inflammatory infiltrates
re usually found at the site of plaque rupture in patients
ying from acute myocardial infarction and stroke (14,15).
herefore, molecular imaging techniques targeting activated
acrophages as a means of noninvasive detection of plaque
Pt. #4
*
*
t. #6
ith Corresponding PET Images
(Patients #1 to #6)
phy (CT) reconstructions are shown in the top panel and corresponding PET
in the aortic wall (Patients #1 to #3, #5 and #6), and 1 patient demonstrated
195 was also noted in the bone marrow (*) and the salivary glands (black
of [11C]-PK11195. Note misalignment and slurring of [11C]-PK11195 signal in*
*
P
ns W
litis
mogra
11195
-PK11
ationulnerability have been proposed (16). Several reports have
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Imaging Vascular Inflammation August 17, 2010:653–61hown the value of [18F]-fluorodeoxyglucose (FDG) for
maging vascular inflammation in patients with large-vessel
asculitis (17–19), and many studies have established FDG
s a useful tool to assess intraplaque inflammatory activity in
therosclerotic disease (20–24). Additionally, the observa-
Pt. #8Pt. #7
Pt. #11Pt. #10
Pt. #14Pt. #13
*
**
Figure 3 Representative [11C]-PK11195 PET/CT Reconstructio
For each patient, [11C]-PK11195 positron emission tomography (PET)/computed to
images are shown in the bottom panel. Note absence of [11C]-PK11195 uptake in
the bone marrow (*) and the salivary glands (white arrowheads). In Patient #13,ion that FDG uptake in atherosclerotic plaques is highly aeproducible (25) paved the way for the first clinical drug
rials using FDG uptake as a surrogate marker for plaque
nflammation (26). However, the glucose analogue FDG is
aken up by any metabolically active tissue, limiting its
pecificity for detecting inflammatory cells. In fact, micro-
Pt. #9
Pt. #12
Pt. #15
*
ith Corresponding PET Images in Controls (Patients #7 to #15)
phy (CT) reconstructions are shown in the top panel and corresponding PET
all of the large arteries. In contrast, high [11C]-PK11195 could be observed in
mmetrically enlarged thyroid gland with increased [11C]-PK11195 was noted.ns W
mogra
the w
an asyutoradiography studies of aortic sections of ApoE/ mice
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August 17, 2010:653–61 Imaging Vascular Inflammationave shown that [14C]-FDG uptake into atherosclerotic
laques correlates poorly with fat content and selective
acrophage staining with anti-CD68 (27). Moreover, de-
pite its utility as a diagnostic tool (17–19), some concerns
ave recently been raised regarding the role of FDG-PET
n the follow-up of patients with large-vessel vasculitis. In
CA, it has been suggested that FDG-PET may fail to
dentify those at risk of relapse (28), whereas Arnaud et al.
Imaging FindingsTable 2 Imaging Findings
Patient # Symptoms
[11C
Visual Uptake
1 Yes Yes
2 Yes Yes
3 Yes Yes
4 Yes Yes
5 Yes Yes
6 Yes Yes
7 No No
8 No No
9 No No
10 No No
11 No No
12 No No
13 No No
14 No No
15 No No
CT  computed tomography; PET  positron emission tomography; T
p=0.005
Symptomatic
n=6
Asymptomatic
n=9
Figure 4
[11C]-PK11195 Uptake in
Regions of Interest Given as TBR for
Asymptomatic Versus Symptomatic Patients
Each box plot shows median (thick lines), quartiles (upper and lower box
boundaries), and extreme values (whiskers) within a category. A cut-off TBR at
1.20 (red dotted line) clearly separated symptomatic from asymptomatic
patients. TBR  target-to-background ratio.t29) reported a poor correlation between FDG uptake and
isease activity in TA. It remains unclear whether persistent
ascular FDG uptake in otherwise clinically inactive pa-
ients reflects persistent granulomatous vasculitis or, alter-
atively, vascular remodeling or metabolically active tissue
n the vicinity of the vessel wall.
PK11195 binds with high affinity to activated cells of the
ononuclear phagocyte lineage. In experimental rat brain
tudies, PET with [11C]-PK11195 detected increased PBR
xpression in activated microglia after ischemic injury (5).
hese findings have been confirmed in patients with neu-
oinflammation (4,30). Laitinen et al. (31) used [3H]-
K11195 in a murine model of atherosclerosis and demon-
trated increased tracer uptake in inflamed plaques,
lthough they also observed nonspecific uptake in the
ealthy vessel wall. It is worth noting, however, that PBR
xpression in the cardiovascular system varies considerably
cross species, and results obtained in rodents may not
ecessarily be translated into humans. PBRs are abundantly
xpressed in vascular smooth cells of rodents (32), but are
bsent in humans (33). More recently, Fujimura et al. (6)
emonstrated specific binding of [3H]-PK11195 to macro-
hages in specimens of human carotid atherosclerotic
laques, but no uptake in vascular smooth muscle cells was
een. In our study, a more than 2-fold increase of TBR was
ound in patients with active disease, which compares well
ith FDG uptake reported in patients with atherosclerosis
21). Conversely, in our control subjects, TBR was 0.98
i.e., equal to background activity), underlining the speci-
city of [11C]-PK11195.
In some minor lesions in patients with active vasculitis,
he [11C]-PK11195 signal may not be strong enough to be
asily detected on PET alone. A previous report by Koba-
ashi et al. (18) using FDG-PET showed that coregistra-
195–Vessel Wall Total PET/CT
Radiation Dose
(mSv)Site TBR
Aortic arch 1.63 8.9
Aortic arch 5.37 7.9
Descending aorta 1.77 7.4
Left carotid 1.28 8.6
Descending aorta 1.33 8.2
Descending aorta 3.05 8.4
— 0.87 8.9
— 1.05 7.9
— 1.07 7.6
— 0.95 7.1
— 1.02 9.0
— 1.09 8.7
— 0.79 7.6
— 0.91 7.8
— 1.04 8.0
rget-to-background ratio.]-PK11ion of PET with contrast-enhanced CT angiography
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Imaging Vascular Inflammation August 17, 2010:653–61ncreased the sensitivity for the detection of vascular inflam-
ation in patients with TA compared with PET alone. The
orphological information provided by CT angiography, in
ddition to allowing better delineation of the vessel wall,
ermits characterization of arterial remodeling and the
xclusion of atherosclerotic disease.
Preliminary findings in patients with carotid atheroscle-
osis suggest that [11C]-PK11195-PET might hold promise
or the detection of intraplaque inflammation. In Figure 5
e show images from 2 patients in whom [11C]-PK11195
ET could distinguish between a recently symptomatic (i.e.,
nstable) and an asymptomatic (i.e., stable) carotid plaque.
hether these findings can be confirmed in a larger
opulation is the subject of ongoing research.
tudy limitations. We acknowledge the relatively limited
ample size in this study. Nonetheless, the study was designed
o assess the feasibility of [11C]-PK11195 PET imaging in
ivo, and albeit limited, this number of patients provided
eaningful interpretation of vascular tracer uptake.
In 3 of our symptomatic patients, PET/CT imaging was
erformed after initiation of systemic steroid therapy. The
umoral mechanisms regulating PBR expression in immune
ells are poorly understood, and it is therefore difficult to
now how steroid therapy affected our imaging results. In
atient #1, we found a decrease in vascular [11C]-PK11195
ptake after a 20-week course of steroids (Fig. 1). However,
his was a single case, and we did not assess whether reduced
11C]-PK11195 uptake was secondary to a decrease in cellular
BR density or a decreased homing of monocytes and conse-
uently lower cell density in inflamed vascular wall.
The proximity of the blood pool and limited thickness of
he arterial wall can result in spillover and partial volume
CBA
Figure 5 [11C]-PK11195 PET/CT in Carotid Atherosclerotic Les
Computed tomography (CT) angiography (A), [11C]-PK11195 positron emission tom
with a 90% left internal carotid artery (ICA) stenosis (solid arrows) who developed
uptake along the convexity of the plaque (B, C, solid arrows). By contrast, D to F
nosis. There is no visible [11C]-PK11195 uptake in the region of the plaque (open
lar gland, and the asterisk denotes high uptake in bone marrow.ffects. However, this should affect asymptomatic and symp-
omatic patients to the same extent and is unlikely to account
or any of the differences observed between the 2 groups.
orrection for spillover and the quantification of receptor
inetics should overcome these potentially confounding fac-
ors, and further quantitative studies are warranted.
The short physical half-life of [11C]-labeled compounds
andates an onsite cyclotron facility, thus limiting its
linical applicability. It also precluded performing a recti-
inear whole-body scan after dynamic data acquisition and,
herefore, restricted PET axial coverage to a 15-cm field of
iew. However, the introduction of new [18F]-labeled PBR
igands, which are currently under pre-clinical investigation
nd have shown high affinity across species in the brain, may
vercome some of these limitations (34).
Finally, the added radiation exposure from PET and CT
emains an important concern, particularly if repeated stud-
es are performed to assess inflammatory activity before and
fter treatment. The total effective radiation dose in our
atients was well below 10 mSv, which is comparable to a
tandard cardiac FDG scan (35). Additionally, we rather
verestimated CT doses, because we used a “chest” weight-
ng factor to estimate doses, whereas a substantial portion of
he scan field of view consisted of “neck,” for which the
eighting factor is 3 times lower.
onclusions
ET with [11C]-PK11195 can be used to assess arterial
nflammatory activity in patients with large-vessel vasculitis
nd may help to stratify patients with active and inactive
isease. Coregistration with contrast-enhanced CT angiog-
FE
*
hy (PET) (B), and PET/CT fusion (C) in a 66-year-old right-handed male patient
al droop and dysphasia 3 weeks before the PET study. Note focal [11C]-PK11195
images in a 78-year-old asymptomatic female patient with an 80% right ICA ste-
s). The black arrowhead denotes high [11C]-PK11195 uptake in the submandibu-D
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ascular wall while providing anatomical information on vessel
all thickening and excluding atherosclerotic disease. These
ndings provide a basis for further studies to evaluate the
otential role of [11C]-PK11195 PET/CT for the detection of
ascular inflammation in atherosclerotic disease.
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